Advances in the treatment of patients with gastric adenocarcinoma

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108
   PubMed Web of Science ®Google Scholar
• The National Board of Health and Welfare: Cancer Incidence in Sweden (2003) 2001. Stockholm, .
   Google Scholar
• Karpeh M, Kelsen D, Tepper J. Cancer – Principles & practice of oncology, V Cancer of the stomach. De Vita, S Hellman, S Rosenberg. Lippincott Williams & Wilkins, Philadelphia 2000; 1092–126
   Google Scholar
• DeVita VTJ, Hellman S, Rosenberg SA. Cancer: Principles and practice of oncology7th ed. Lippincott Williams & Wilkins, Philadelphia 2005
   Google Scholar
• Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752–5
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163–8
   PubMed Web of Science ®Google Scholar
• Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37–41
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587–91
   PubMed Web of Science ®Google Scholar
• Lehnert KB. Techniques of reconstruction after total gastrectomy for cancer. Br J Surg 2004; 91: 528–39
   PubMed Web of Science ®Google Scholar
• McCulloch P. Should general surgeons treat gastric carcinoma? An audit of practice and results, 1980–1985. Br J Surg 1994; 81: 417–20
   PubMed Web of Science ®Google Scholar
• Gouzi JL, Huguier M, Fagniez PL, Launois B, Flamant Y, Lacaine F, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 1989; 209: 162–6
   PubMed Web of Science ®Google Scholar
• Robertson CS, Chung SC, Woods SD, Griffin SM, Raimes SA, Lau JT, et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994; 220: 176–82
   PubMed Web of Science ®Google Scholar
• Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer: Five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999; 230: 170–8
   PubMed Web of Science ®Google Scholar
• Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908–14
   PubMed Web of Science ®Google Scholar
• Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522–30
   PubMed Web of Science ®Google Scholar
• Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22: 2069–77
   PubMed Web of Science ®Google Scholar
• McCulloch, P, Nita, ME, Kazi, H, Gama-Rodrigues, J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2004: CD001964.
   PubMedGoogle Scholar
• Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004; 91: 283–7
   PubMed Web of Science ®Google Scholar
• Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988; 75: 110–2
   PubMed Web of Science ®Google Scholar
• Liedman B, Bosaeus I, Hugosson I, Lundell L. Long-term beneficial effects of a gastric reservoir on weight control after total gastrectomy: A study of potential mechanisms. Br J Surg 1998; 85: 542–7
   PubMed Web of Science ®Google Scholar
• Svedlund J, Sullivan M, Liedman B, Lundell L. Long term consequences of gastrectomy for patient's quality of life: The impact of reconstructive techniques. Am J Gastroenterol 1999; 94: 438–45
   PubMed Web of Science ®Google Scholar
• Fuchs, KH, Thiede, A, Engemann, R, Deltz, E, Stremme, O, Hamelmann, H. Reconstruction of the food passage after total gastrectomy: Randomized trial. World J Surg 1995;19:698–705; Discussion –6.
   PubMed Web of Science ®Google Scholar
• Schwarz, A, Buchler, M, Usinger, K, Rieger, H, Glasbrenner, B, Friess, H, et al. Importance of the duodenal passage and pouch volume after total gastrectomy and reconstruction with the Ulm pouch: Prospective randomized clinical study. World J Surg 1996;20:60–6; Discussion 6–7.
   PubMed Web of Science ®Google Scholar
• Nakane Y, Okumura S, Akehira K, Okamura S, Boku T, Okusa T, et al. Jejunal pouch reconstruction after total gastrectomy for cancer. A randomized controlled trial. Ann Surg 1995; 222: 27–35
   PubMed Web of Science ®Google Scholar
• Iivonen MK, Mattila JJ, Nordback IH, Matikainen MJ. Long-term follow-up of patients with jejunal pouch reconstruction after total gastrectomy. A randomized prospective study. Scand J Gastroenterol 2000; 35: 679–85
   PubMed Web of Science ®Google Scholar
• Liedman B, Andersson H, Berglund B, Bosaeus I, Hugosson I, Olbe L, et al. Food intake after gastrectomy for gastric carcinoma: The role of a gastric reservoir. Br J Surg 1996; 83: 1138–43
   PubMed Web of Science ®Google Scholar
• Yoo CH, Sohn BH, Han WK, Pae WK. Proximal gastrectomy reconstructed by jejunal pouch interposition for upper third gastric cancer: Prospective randomized study. World J Surg 2005; 29: 1592–9
   PubMedGoogle Scholar
• Uenosono Y, Natsugoe S, Ehi K, Arigami T, Hokita S, Aikou T. Detection of sentinel nodes and micrometastases using radioisotope navigation and immunohistochemistry in patients with gastric cancer. Br J Surg 2005; 92: 886–9
   PubMedGoogle Scholar
• Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg 2002; 168: 597–608
   PubMedGoogle Scholar
• Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441–7
   PubMed Web of Science ®Google Scholar
• Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35: 1059–64
   PubMed Web of Science ®Google Scholar
• Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11: 837–43
   PubMed Web of Science ®Google Scholar
• Panzini I, Gianni L, Fattori PP, Tassinari D, Imola M, Fabbri P, et al. Adjuvant chemotherapy in gastric cancer: A meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002; 88: 21–7
   PubMed Web of Science ®Google Scholar
• Hu JK, Chen ZX, Zhou ZG, Zhang B, Tian J, Chen JP, et al. Intravenous chemotherapy for resected gastric cancer: Meta-analysis of randomized controlled trials. World J Gastroenterol 2002; 8: 1023–8
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725–30
   PubMed Web of Science ®Google Scholar
• Smalley SR, Gunderson L, Tepper J, Martenson JA, Jr, Minsky B, Willett C, et al. Gastric surgical adjuvant radiotherapy consensus report: Rationale and treatment implementation. Int J Radiat Oncol Biol Phys 2002; 52: 283–93
   PubMed Web of Science ®Google Scholar
• Tepper JE, Gunderson LL. Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. Semin Radiat Oncol 2002; 12: 187–95
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PWT, Crane CH, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. J Clin Oncol 2006; 24: 3953–8
   PubMed Web of Science ®Google Scholar
• Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993; 85: 1839–44
   PubMedGoogle Scholar
• Fink U, Schuhmacher C, Stein HJ, Busch R, Feussner H, Dittler HJ, et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: Feasibility, response and outcome after complete resection. Br J Surg 1995; 82: 1248–52
   PubMedGoogle Scholar
• Rougier P, Mahjoubi M, Lasser P, Ducreux M, Oliveira J, Ychou M, et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma–a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 1994; 30A: 1269–75
   PubMedGoogle Scholar
• Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, et al. Neoadjuvant therapy of high-risk gastric cancer: A phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 1996; 14: 1818–28
   PubMedGoogle Scholar
• Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11–20
   PubMed Web of Science ®Google Scholar
• Ychou M, Pignon JP, Lasser P, Conroy T, Bouche O, Boige V, et al. Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (P) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC 94012-FFCD 9703 trial. J Clin Oncol 2006; 24: 185s(abstr 4026)
   Google Scholar
• Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261–7
   PubMed Web of Science ®Google Scholar
• Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996–2004
   PubMed Web of Science ®Google Scholar
• Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903–9
   PubMed Web of Science ®Google Scholar
• Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F, et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. J Clin Oncol (Meeting Abstracts) 2006; 24: LBA4017
   Google Scholar
• Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: Results of a randomized phase II study. Ann Oncol 2004; 15: 1773–81
   PubMed Web of Science ®Google Scholar
• Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study–FFCD 9803. J Clin Oncol 2004; 22: 4319–28
   PubMed Web of Science ®Google Scholar
• Moehler M, Eimermacher A, Siebler J, Hohler T, Wein A, Menges M, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92: 2122–8
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005; 50: 2218–23
   PubMed Web of Science ®Google Scholar
• Kohne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: A phase II multicentric trial. Br J Cancer 2003; 89: 997–1001
   PubMed Web of Science ®Google Scholar
• Dank M, Zaluski J, Barone C, Valvere V, Peschel C, Wenczl M. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folininc acid (FA) vs CDP + 5FU in 1st-line advanced gastric cancer patients. J Clin Oncol 2005; 23: 308s(Abstr: 4003)
   Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group. J Clin Oncol 2006; 24: 4991–7
   PubMed Web of Science ®Google Scholar
• Roth AD, Maibach R, Falk S, Stupp R, Saletti P, Käberle M, et al. Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cispaltin (TC) versus epirubicin-cisplatin-FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Annual Meeting Proceedings ASCO 2004; 23: 317(Abstr: 4020)
   Google Scholar
• Kang Y, Kang WK, Shin DB, Chen J, Xiong J, Wang J. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced fgastric cancer (AGC): Efficacy and safety results. J Clin Oncol 2006; 24: 934s(Abstr:LBA4015)
   Google Scholar
• Baek JH, Kim JG, Jeon SB, Chae YS, Kim DH, Sohn SK, et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2006; 94: 1407–11
   PubMed Web of Science ®Google Scholar
• Fuchs C, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M. A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). J Clin Oncol 2006; 24: 147s(Abstr: 3506)
   Google Scholar
• Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005; 23: 6957–65
   PubMed Web of Science ®Google Scholar
• Ajani JA, Lee F-C, Singh DA, Haller DG, Lenz H-J, Benson AB, III, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 663–7
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183–232
   PubMed Web of Science ®Google Scholar
• Doi T, Koizumi W, Siena S, Cascinu S, Ohtsu A, Michael M, et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. J Clin Oncol (Meeting Abstracts) 2003; 22
   Google Scholar
• Enzinger, PC, Fidias, P, Meyerhardt, J, Stuart, K, Fuchs, C, Huberman, M, et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. Proc Gastrointestinal Am SOc Clin Oncol Symposium. 2006.
   Google Scholar
• Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial. Br J Cancer 2002; 86: 1864–70
   PubMed Web of Science ®Google Scholar
• Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: High incidence in patients receiving irinotecan- and bevacizumab-based therapy 10.1200/JCO.2005.81.908. J Clin Oncol ;23 2005; 23: 2574–6
   PubMed Web of Science ®Google Scholar
• Butler, E, Shukla, V, Teh, B, Lu, H, Paulino, A. Novel strategies for improving delineation in pancreas and stomach cancer Using evidence based standardized treatment maps. Int J Radiat Oncol Biol Phys 2006;66:S309. Abstr:2179.
   Google Scholar
• Hong, T, Crowley, E, Tsai, H, Blake, M, Napolitano, B, Kachnic, L. A 3-Dimensional CT-based atlas for radiation planning in gastric cancer: Target delineation and implications for treatment planning. Int J Radiat Oncol Biol Phys 2006;66:S294. Abstr:2150.
   Google Scholar